New study aims to unlock immune secrets in seniors with flu, RSV, and COVID-19
NCT ID NCT07643688
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This observational study will follow 150 adults aged 60 and older who have a respiratory viral infection (influenza, RSV, or COVID-19) or who test negative. Researchers will measure immune markers like PD-L1 and inflammatory proteins in blood samples taken shortly after symptoms start and again a few days later. The goal is to understand how the immune system responds during the infection and to find markers that could predict who will get sicker. This study does not test any treatment, but the results could guide future therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify biomarkers that help predict disease severity and point toward new treatments targeting the immune system for respiratory viral infections.
What could go wrong
This is an early observational study with only 150 participants, so findings may not apply broadly. It does not test any treatment, so direct patient benefits are not expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.